An observational study in Genetic Predisposition to Disease and Genetics Disease, sponsored by Helix, Inc. Recruiting at 14 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Helix, Inc · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one has the largest planned enrollment of the 50 observational ones that give a count, is one of 10 that started in 2021, is one of 50 observational ones, reaches primary completion later than 41 of the 45 other live ones, and was the 67th registered.
242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.
Browse Genetic Predisposition to Disease studies →37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:
University of Missouri-Columbia · Sites in United States
Ages 45–65 · Women only · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 45–74 · Women only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Women only
Christopher Reilly · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000,000 is above the median of 500 across 154 observational studies indexed under Genetic Predisposition to Disease.
Median enrollment 225 across the 37 interventional studies, 560 across the 50 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 87 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Helix, Inc as lead sponsor.
Helix, Inc has 1 study filed under Genetic Predisposition to Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Genetic Predisposition to Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05205356Boston Children's HospitalVIGOR: Virtual Genome Center for Infant Health | 2026-12-31 |
| NCT05020574University of California, San FranciscoMicrobiome and Association With Implant Infections | 2026-12-31 |
| NCT06962059Abramson Cancer Center at Penn MedicineHealthy Volunteers Study | 2027-01-15 |
| NCT06450171Dana-Farber Cancer InstituteEvaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study | 2027-01-31 |
| NCT05161169Brigham and Women's HospitalImplementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants | 2027-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other multi-omics data into clinical care.
The network will create a large-scale clinicogenomics dataset, which will support research to discover molecular and genetic determinants of disease risk, disease progression, treatment response, health economic outcomes, social or behavioral determinants of health, targets for therapeutic intervention, risk stratification, clinical implementation, and other clinical indicators of interest. This clinicogenomics dataset will be used to reveal molecular and/or genetic factors that could improve the diagnosis or medical treatment of individual participants and includes a process to share individual results with participants. Participants will also receive annual reports on study outcomes and the impact of HRN, as such information becomes available.
Institutional membership in HRN will consist of Helix and member healthcare systems (herein referred to as "HRN Member Site(s)"). The Helix Research Network is a multi-center research program that will enroll an unlimited number of participants. Participants will be recruited concurrently from HRN Member Sites. In some cases, HRN Member Sites may recruit participants from multiple clinical sites. Participants who meet the enrollment criteria established in this protocol will be enrolled if they or their legally authorized representative(s) provide informed consent in accordance with all applicable regulations and sIRB requirements. Participants will be enrolled until withdrawal from the study or end of the study. Participants may be recruited at any point during the study period, until the recruitment goals established by the protocol are met.
The study will recruit the general population from the surrounding areas of the HRN Member Sites. This may include patients within a health system of the Site or community members in the surrounding area of Sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exome sequencing will be completed on each sample submitted.
Establish a Research Network
Establish a research network to support the advancement of biomedical research, improve human health through genomics research, and accelerate integration of genomic and other omics data into clinical care.
Time frame: Through study completion, average 10 years
Aggregate data
Aggregate molecular, genomic data, phenotypic and other health-related data in centralized and/or federated databases to be accessed by investigators for approved research purposes.
Time frame: Through study completion, average 10 years
Re-Contact participants
Recontact participants for additional data collection, research participation opportunities, and return of results
Time frame: Through study completion, average 10 years
Genetic biomarker identification
Identification and characterization of clinical, histological, molecular, and genetic biomarkers that are linked to disease, disease outcomes, or that might be used to improvise disease classification.
Time frame: Through study completion, average 10 years
Exploration of genetic determinants of disease
Exploration of the molecular and genetic underpinnings and determinants of disease, including disease risk, disease progression, treatment response, health economic outcomes, social or behavioral determinants of health, targets for therapeutic intervention, risk stratification, and other clinical indicators of interest.
Time frame: Through study completion, average 10 years
Collection and analysis of Patient Reported Outcomes
Collection and analysis of Patient Reported Outcomes (e.g. quality of life, physical function, symptom burden) associated with diseases that have a genetic or molecular etiology. Validation of disease-specific instruments to assess the impact of genetic screening.
Time frame: Through study completion, average 10 years
Plan to share: Yes — As a population health research network, the primary purpose of HRN is to help researchers and clinicians better understand how genetic information may be used to improve the health of individuals and communities. It is possible that participants may receive actionable health information as a result of analysis of their DNA information. This means that the participant's genetic results may be used by their healthcare providers to inform medical decisions. It is also possible that novel discoveries may be generated from the research that could positively impact a participant's healthcare in the future.
Supporting information: Informed consent form, Clinical study report
Time frame: Data will be available for the duration of the study.
Access criteria: An application to the Helix Research Network or a Member Site for Member Site level data.
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Sep 2031, 120 months after the start.
Of 82 observational studies under Genetic Predisposition to Disease, half reached primary completion within 96 months of starting (the median), counting those still running; a quarter within 52. This study's planned 120 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genetic Predisposition to Disease →